Search

Your search keyword '"Halperin, Daniel M."' showing total 305 results
Start Over Author "Halperin, Daniel M."
305 results on '"Halperin, Daniel M."'

3. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists

Author

Galgano, Samuel J., Morani, Ajaykumar C., Gopireddy, Dheeraj R., Sharbidre, Kedar, Bates, David D. B., Goenka, Ajit H., Arif-Tiwari, Hina, Itani, Malak, Iravani, Amir, Javadi, Sanaz, Faria, Silvana, Lall, Chandana, Bergsland, Emily, Verma, Sadhna, Francis, Isaac R., Halperin, Daniel M., Chatterjee, Deyali, Bhosale, Priya, and Yano, Motoyo

Published
2022
Full Text
View/download PDF

4. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19

Author

Bergsland, Emily K, Halperin, Daniel M, Dillon, Joseph S, Dasari, N Arvind, Kunz, Pamela L, Soares, Heloisa P, Pryma, Daniel, Bodei, Lisa, Hope, Thomas, Soulen, Michael C, Mailman, Josh, and Howe, James R

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Good Health and Well Being, Betacoronavirus, COVID-19, Coronavirus Infections, Health Personnel, Humans, Infectious Disease Transmission, Patient-to-Professional, Infectious Disease Transmission, Professional-to-Patient, Neuroendocrine Tumors, North America, Occupational Diseases, Occupational Exposure, Pandemics, Pneumonia, Viral, SARS-CoV-2, Societies, Medical, Clinical Sciences, Gastroenterology & Hepatology, Clinical sciences
Published
2020

6. Contributors

Author

Abdalla, Eddie K., primary, Ahuja, Jitesh, additional, Aluja-Jaramillo, Felipe, additional, Amaria, Rodabe N., additional, Amini, Behrang, additional, Avram, Anca, additional, Avritscher, Rony, additional, Bedrosian, Isabelle, additional, Betancourt-Cuellar, Sonia L., additional, Bhosale, Priya R., additional, Bishop, Andrew J., additional, Bronstein, Yulia, additional, Burgan, Constantine M., additional, Tran Cao, Hop S., additional, Chainitikun, Sudpreeda, additional, Chang, Joe Y., additional, J.Chery, Lisly, additional, Chuang, Hubert H., additional, Coleman, Aaron, additional, Costelloe, Colleen M., additional, Das, Prajnan, additional, DeJesus, Reordan, additional, Devine, Catherine, additional, Eifel, Patricia J., additional, Erasmus, Jeremy J., additional, C.Faria, Silvana, additional, Fleming, Jason B., additional, Galgano, Samuel J., additional, Ganeshan, Dhakshinamoorthy, additional, Garg, Naveen, additional, Garvey, Patrick B., additional, Gladish, Gregory, additional, Guo, Chunxiao, additional, Gutiérrez, Fernando R., additional, Halperin, Daniel M., additional, Hanafy, Abdelrahman K., additional, Hoffman, Karen, additional, Hofstetter, Wayne L., additional, Hwu, Wen-Jen, additional, Ibarra Rovira, Juan J., additional, Ibrahim, Mohannad, additional, Ikoma, Naruhiko, additional, Iyer, Revathy B., additional, Javadi, Sanaz, additional, Javle, Milind, additional, Jensen, Corey T., additional, Jonasch, Eric, additional, Kamat, Aparna, additional, Kamat, Ashish, additional, Kambadakone, Avinash R., additional, Kaufman, Gregory P., additional, Kaur, Amritjot, additional, Kaur, Harmeet, additional, Rao Korivi, Brinda, additional, Kumar, Rajendra, additional, Kundra, Vikas, additional, Kuperman Benveniste, Marcelo F., additional, Le, Ott, additional, Lee, Jeffrey H., additional, LePetross, Huang, additional, Lin, Patrick P., additional, Ludwig, Joseph A., additional, Macapinlac, Homer A., additional, Madewell, John E., additional, Mansfield, Paul, additional, Marcal, Leonardo P., additional, Marom, Edith M., additional, Massini, Tara, additional, Matamoros, Aurelio, additional, Frances McAleer, Mary, additional, Mehran, Reza J., additional, Menias, Christine, additional, Morani, Ajaykumar C., additional, Morris, Van K., additional, Moulder-Thompson, Stacy L., additional, Mujtaba, Bilal, additional, Mukherji, Suresh K., additional, Nassar, Sameh, additional, Nguyen, Quynh-Nhu, additional, Noda, Yoshifumi, additional, Onn, Amir, additional, Overman, Michael J., additional, C. Pagliaro, Lance, additional, Palacio, Diana P., additional, Parakh, Anushri, additional, Parmar, Hemant A., additional, Patel, Shreyaskumar, additional, Patnana, Madhavi, additional, Phan, Alexandria, additional, Pokhylevych, Halyna, additional, Porter, Kristin K., additional, Rauch, Gaiane M., additional, Raval, Bharat, additional, Rodriguez-Bigas, Miguel, additional, Rohren, Eric M., additional, Roland, Christina L., additional, Ross, Jeremy, additional, Sabloff, Bradley S., additional, Sagebiel, Tara, additional, Sahani, Dushant V., additional, Schmeler, Kathleen M., additional, Shroff, Girish, additional, Siefker-Radtke, Arlene O, additional, Smith, Elainea N., additional, Jason Stafford, R., additional, Stewart, David J., additional, Strange, Chad D., additional, Swisher, Stephen G., additional, Taher, Ahmed, additional, Heng Tan, Cher, additional, Truong, Mylene T., additional, Ueno, Naoto T., additional, Varadhachary, Gauri R., additional, Venkatesan, Aradhana M., additional, Verschraegen, Claire F., additional, Vikram, Raghunandan, additional, J.Vinnicombe, Sarah, additional, Virarkar, Mayur K., additional, Viswanathan, Chitra, additional, Westin, Jason R., additional, Woodward, Wendy A., additional, and Kuan Yu, T., additional

Published
2023
Full Text
View/download PDF

10. Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

11. Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Tables from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

13. TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

14. Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

17. Correlation of cancer testis antigen expression with high type-I interferon signal and prognosis in small bowel neuroendocrine tumors.

Author

Ayabe, Reed I., primary, Seo, Yongwoo David, additional, Melendez, Brenda, additional, Lazcano Segura, Rossana, additional, Fields, Brittany C., additional, Wani, Khalida M., additional, Johnson, Sarah, additional, Witt, Russell, additional, Chelvanambi, Manoj, additional, Hudgens, Courtney, additional, Hernandez, Sharia D., additional, Ajami, Nadim J., additional, Wargo, Jennifer Ann, additional, Lazar, Alexander J., additional, Halperin, Daniel M., additional, Estrella, Jeannelyn, additional, and Maxwell, Jess, additional

Published
2024
Full Text
View/download PDF

18. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

Author

Singh, Simron, primary, Halperin, Daniel M., additional, Myrehaug, Sten, additional, Herrmann, Ken, additional, Pavel, Marianne, additional, Kunz, Pamela L., additional, Chasen, Beth, additional, Capdevila, Jaume, additional, Tafuto, Salvatore, additional, Oh, Do-Youn, additional, Yoo, Changhoon, additional, Falk, Stephen, additional, Halfdanarson, Thorvardur Ragnar, additional, Folitar, Ilya, additional, Zhang, Yufen, additional, Santoro, Paola, additional, Aimone, Paola, additional, de Herder, Wouter W., additional, and Ferone, Diego, additional

Published
2024
Full Text
View/download PDF

19. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

Author

Vijayvergia, Namrata, Dasari, Arvind, Deng, Mengying, Litwin, Samuel, Al-Toubah, Taymeyah, Alpaugh, R. Katherine, Dotan, Efrat, Hall, Michael J., Ross, Nicole M., Runyen, Melissa M., Denlinger, Crystal S., Halperin, Daniel M., Cohen, Steven J., Engstrom, Paul F., and Strosberg, Jonathan R.

Published
2020
Full Text
View/download PDF

22. Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

23. Data from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

24. Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

25. Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

26. Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

27. Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

28. Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

29. Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

30. Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

31. Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

34. [ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

Author

Singh, Simron, Halperin, Daniel M., Myrehaug, Sten, Herrmann, Ken, Pavel, Marianne, Kunz, Pamela L., Chasen, Beth, Capdevila, Jaume, Tafuto, Salvatore, Oh, Do-Youn, Yoo, Changhoon, Falk, Stephen, Halfdanarson, Thorvardur Ragnar, Folitar, Ilya, Zhang, Yufen, Santoro, Paola, Aimone, Paola, de Herder, Wouter W., and Ferone, Diego

Published
2024
Full Text
View/download PDF

36. Blood-based Proteomic Signatures Associated With MENI-related Duodenopancreatic Neuroendocrine Tumor Progression.

Author

Fahrmann, Johannes F., Wasylishen, Amanda R., Pieterman, Carolina R. C., Irajizad, Ehsan, Vykoukal, Jody, Wu, Ranran, Dennison, Jennifer B., Peterson, Christine B., Hua Zhao, Kim-Anh Do, Halperin, Daniel M., Agarwal, Sunita K., Blau, Jenny E., Jha, Smita, Del Rivero, Jaydira, Nilubol, Naris, Walter, Mary F., Welch, James M., Weinstein, Lee S., and Vriens, Menno R.

Subjects
NEUROENDOCRINE tumors, MASS spectrometry, DISEASE progression
Abstract

Purpose: Patients with multiple endocrine neoplasia type 1 (MEN1) are predisposed to develop duodenopancreatic neuroendocrine tumors (dpNETs), and metastatic dpNET is the primary cause of disease-related mortality. Presently, there is a paucity of prognostic factors that can reliably identify patients with MEN1-related dpNETS who are at high risk of distant metastasis. In the current study, we aimed to establish novel circulating molecular protein signatures associated with disease progression. Experimental Design: Mass spectrometry-based proteomic profiling was conducted on plasmas procured through an international collaboration between MD Anderson Cancer Center, the National Institutes of Health, and the University Medical Center Utrecht from a cohort of 56 patients with MEN1 [14 with distant metastasis dpNETs (cases) and 42 with either indolent dpNETs or no dpNETs (controls)]. Findings were compared to proteomic profiles generated from serially collected plasmas from a mouse model of Men1-pancreatic neuroendocrine tumors (Men1fl/flPdx1-CreTg) and control mice (Men1fl/fl). Results: A total of 187 proteins were found to be elevated in MEN1 patients with distant metastasis compared to controls, including 9 proteins previously associated with pancreatic cancer and other neuronal proteins. Analyses of mouse plasmas revealed 196 proteins enriched for transcriptional targets of oncogenic MYCN, YAP1, POU5F1, and SMAD that were associated with disease progression in Men1fl/flPdx1-CreTg mice. Cross-species intersection revealed 19 proteins positively associated with disease progression in both human patients and in Men1fl/flPdx1-CreTg mice. Conclusions: Our integrated analyses identified novel circulating protein markers associated with disease progression in MEN1-related dpNET. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

Author

Halfdanarson, Thorvardur R., Strosberg, Jonathan R., Tang, Laura, Bellizzi, Andrew M., Bergsland, Emily K., OʼDorisio, Thomas M., Halperin, Daniel M., Fishbein, Lauren, Eads, Jennifer, Hope, Thomas A., Singh, Simron, Salem, Riad, Metz, David C., Naraev, Boris G., Reidy-Lagunes, Diane L., Howe, James R., Pommier, Rodney F., Menda, Yusuf, and Chan, Jennifer A.

Published
2020
Full Text
View/download PDF

38. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, additional, Andersson, Borje S., additional, Mendrzyk, Regina, additional, Alpert, Amir, additional, Wagner, Claudia, additional, Nowak, Anna, additional, Aslan, Katrin, additional, Satelli, Arun, additional, Richter, Fabian, additional, Kuttruff-Coqui, Sabrina, additional, Schoor, Oliver, additional, Fritsche, Jens, additional, Coughlin, Zoe, additional, Mohamed, Ali S., additional, Sieger, Kerry, additional, Norris, Becky, additional, Ort, Rita, additional, Beck, Jennifer, additional, Vo, Henry Hiep, additional, Hoffgaard, Franziska, additional, Ruh, Manuel, additional, Backert, Linus, additional, Wistuba, Ignacio I., additional, Fuhrmann, David, additional, Ibrahim, Nuhad K., additional, Morris, Van Karlyle, additional, Kee, Bryan K., additional, Halperin, Daniel M., additional, Nogueras-Gonzalez, Graciela M., additional, Kebriaei, Partow, additional, Shpall, Elizabeth J., additional, Vining, David, additional, Hwu, Patrick, additional, Singh, Harpreet, additional, Reinhardt, Carsten, additional, Britten, Cedrik M., additional, Hilf, Norbert, additional, Weinschenk, Toni, additional, Maurer, Dominik, additional, and Walter, Steffen, additional

Published
2023
Full Text
View/download PDF

39. Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, primary, Overman, Michael J., primary, Willett, Anneleis F., primary, Knafl, Mark, primary, Fu, Szu-Chin, primary, Malpica, Anais, primary, Prasad, Seema, primary, Royal, Richard E., primary, Scally, Christopher P., primary, Mansfield, Paul F., primary, Wistuba, Ignacio I., primary, Futreal, Andrew P., primary, Maru, Dipen M., primary, Solis Soto, Luisa M., primary, Parra Cuentas, Edwin R., primary, Chen, Honglei, primary, Villalobos, Pamela, primary, Verma, Anuj, primary, Mahvash, Armeen, primary, Hwu, Patrick, primary, Cortazar, Patricia, primary, McKenna, Edward, primary, Yun, Cindy, primary, Dervin, Shannon, primary, Schulze, Katja, primary, Darbonne, Walter C., primary, Morani, Ajaykumar C., primary, Kopetz, Scott, primary, Fournier, Keith F., primary, Woodman, Scott E., primary, Yao, James C., primary, Varadhachary, Gauri R., primary, and Halperin, Daniel M., primary

Published
2023
Full Text
View/download PDF

40. Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, primary, Overman, Michael J., primary, Willett, Anneleis F., primary, Knafl, Mark, primary, Fu, Szu-Chin, primary, Malpica, Anais, primary, Prasad, Seema, primary, Royal, Richard E., primary, Scally, Christopher P., primary, Mansfield, Paul F., primary, Wistuba, Ignacio I., primary, Futreal, Andrew P., primary, Maru, Dipen M., primary, Solis Soto, Luisa M., primary, Parra Cuentas, Edwin R., primary, Chen, Honglei, primary, Villalobos, Pamela, primary, Verma, Anuj, primary, Mahvash, Armeen, primary, Hwu, Patrick, primary, Cortazar, Patricia, primary, McKenna, Edward, primary, Yun, Cindy, primary, Dervin, Shannon, primary, Schulze, Katja, primary, Darbonne, Walter C., primary, Morani, Ajaykumar C., primary, Kopetz, Scott, primary, Fournier, Keith F., primary, Woodman, Scott E., primary, Yao, James C., primary, Varadhachary, Gauri R., primary, and Halperin, Daniel M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, primary, Overman, Michael J., primary, Willett, Anneleis F., primary, Knafl, Mark, primary, Fu, Szu-Chin, primary, Malpica, Anais, primary, Prasad, Seema, primary, Royal, Richard E., primary, Scally, Christopher P., primary, Mansfield, Paul F., primary, Wistuba, Ignacio I., primary, Futreal, Andrew P., primary, Maru, Dipen M., primary, Solis Soto, Luisa M., primary, Parra Cuentas, Edwin R., primary, Chen, Honglei, primary, Villalobos, Pamela, primary, Verma, Anuj, primary, Mahvash, Armeen, primary, Hwu, Patrick, primary, Cortazar, Patricia, primary, McKenna, Edward, primary, Yun, Cindy, primary, Dervin, Shannon, primary, Schulze, Katja, primary, Darbonne, Walter C., primary, Morani, Ajaykumar C., primary, Kopetz, Scott, primary, Fournier, Keith F., primary, Woodman, Scott E., primary, Yao, James C., primary, Varadhachary, Gauri R., primary, and Halperin, Daniel M., primary

Published
2023
Full Text
View/download PDF

42. Blood-based proteomic signatures associated with MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression

Author

Cancer, MS Endocriene Oncologie, Heelkunde Opleiding, MS CGO, Fahrmann, Johannes F, Wasylishen, Amanda R, Pieterman, Carolina R C, Irajizad, Ehsan, Vykoukal, Jody, Wu, Ranran, Dennison, Jennifer B, Peterson, Christine B, Zhao, Hua, Do, Kim-Anh, Halperin, Daniel M, Agarwal, Sunita K, Blau, Jenny E, Jha, Smita, Rivero, Jaydira Del, Nilubol, Naris, Walter, Mary F, Welch, James M, Weinstein, Lee S, Vriens, Menno R, van Leeuwaarde, Rachel S, van Treijen, Mark J C, Valk, Gerlof D, Perrier, Nancy D, Hanash, Samir M, Katayama, Hiroyuki, Cancer, MS Endocriene Oncologie, Heelkunde Opleiding, MS CGO, Fahrmann, Johannes F, Wasylishen, Amanda R, Pieterman, Carolina R C, Irajizad, Ehsan, Vykoukal, Jody, Wu, Ranran, Dennison, Jennifer B, Peterson, Christine B, Zhao, Hua, Do, Kim-Anh, Halperin, Daniel M, Agarwal, Sunita K, Blau, Jenny E, Jha, Smita, Rivero, Jaydira Del, Nilubol, Naris, Walter, Mary F, Welch, James M, Weinstein, Lee S, Vriens, Menno R, van Leeuwaarde, Rachel S, van Treijen, Mark J C, Valk, Gerlof D, Perrier, Nancy D, Hanash, Samir M, and Katayama, Hiroyuki

Published
2023

47. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.

Author

Singh, Simron, Hope, Thomas A, Bergsland, Emily B, Bodei, Lisa, Bushnell, David L, Chan, Jennifer A, Chasen, Beth R, Chauhan, Aman, Das, Satya, Dasari, Arvind, Rivero, Jaydira Del, El-Haddad, Ghassan, Goodman, Karyn A, Halperin, Daniel M, Lewis, Mark A, Lindwasser, O Wolf, Myrehaug, Sten, Raj, Nitya P, Reidy-Lagunes, Diane L, and Soares, Heloisa P

Subjects
NEUROENDOCRINE tumors, CLINICAL trials, MEETING planning, AMINO acid sequence, PEPTIDE receptors
Abstract

Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of 177Lu-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included 1) PRRT re-treatment, 2) PRRT and immunotherapy combinations, 3) PRRT and DNA damage repair inhibitor combinations, 4) treatment for liver-dominant disease, 5) treatment for PRRT-resistant disease, and 6) dosimetry-modified PRRT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.

Author

Halfdanarson, Thorvardur Ragnar, primary, Capdevila, Jaume, additional, Halperin, Daniel M., additional, Herrmann, Ken, additional, Kong, Grace, additional, Leyden, Simone, additional, Mailman, Josh, additional, Reidy-Lagunes, Diane, additional, Srirajaskanthan, Rajaventhan, additional, Erdö, Máté, additional, Rotger, Amanda, additional, and Thevenet, Thomas, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results